Evidence map›Paper›PMID 35998226›Full record

ArticleCancer biology & therapy2022

BMSC-derived exosomal lncRNA PTENP1 suppresses the malignant phenotypes of bladder cancer by upregulating SCARA5 expression.

Shu-Cheng Liu, You-Han Cao, Li-Bo Chen, Ran Kang, Zhong-Xin Huang, Xin-Sheng Lu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biology & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Natural Products Treat Colorectal Cancer by Regulating miRNA.Pharmaceuticals (Basel, Switzerland) · 2023
    Review
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Shu-Cheng LiuThe First Affiliated Hospital, Department of Urology, Hengyang Medical School, University of South China, Hengyang, China.
You-Han CaoThe First Affiliated Hospital, Department of Urology, Hengyang Medical School, University of South China, Hengyang, China.
Li-Bo ChenThe First Affiliated Hospital, Department of Urology, Hengyang Medical School, University of South China, Hengyang, China.
Ran KangThe First Affiliated Hospital, Department of Urology, Hengyang Medical School, University of South China, Hengyang, China.
Zhong-Xin HuangThe First Affiliated Hospital, Department of Urology, Hengyang Medical School, University of South China, Hengyang, China.
Xin-Sheng LuThe First Affiliated Hospital, Department of Urology, Hengyang Medical School, University of South China, Hengyang, China.ORCID 0000-0002-0168-4358
University of South China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

LncRNAs can be transported to tumor cells where they exert regulatory effects by bone marrow mesenchymal stem cells (BMSC)-derived exosomes. Here, we aimed to investigate the functional mechanism of BMSC-derived exosomal lncRNA PTENP1 in the progression of bladder cancer (BC). Methods of BMSC were identified by detecting surface markers through flow cytometry. Exosomes from BMSC were identified by transmission electron microscopy, nanoparticle tracking analysis (NTA), and western blot analysis of exosome markers. Cellular internalization of BMSC-derived exosomes (BMSC-Exo) into BC cells was detected by confocal microscopy. CCK-8, colony formation, flow cytometry, wound healing, and transwell assays were adopted to estimate cell proliferation, apoptosis, migration, and invasion abilities, respectively. Interplay between miR-17 and lncRNA PTENP1 or SCARA5 was verified by dual-luciferase reporter, RNA pull down, and/or RNA immunoprecipitation (RIP) assays. Tumor xenograft assay was conducted in nude mice to study the role of exosomal lncRNA PTENP1 in BC progression

Indexed as

ExosomesMesenchymal Stem CellsMicroRNAsRNA, Long NoncodingUrinary Bladder NeoplasmsAnimalsCell ProliferationHumansMiceMice, NudePhenotypeScavenger Receptors, Class AMicroRNAsRNA, Long NoncodingSCARA5 protein, humanSCARA5 protein, mouseScavenger Receptors, Class ABladder cancerbone marrow mesenchymal stem cellsexosomeslong non-coding RNA PTENP1MicroRNA-17SCARA5

Identifiers

PMID35998226
PMCPMC9415615
OpenAlexW4292838578

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.